Endo International Plc said it would purchase Auxilium Pharmaceuticals Inc in a deal valued at $2.6 billion, including the repayment and assumption of debt. Endo's offer of $33.25 per share represents a premium of about 12 percent to Auxilium's Wednesday close and is higher than Endo's previous offer of $28.10.The deal has an equity value of $1.67 billion, according to a Reuters calculation.As part of the deal, Auxilium terminated its proposed merger agreement with Canadian eye-drug maker QLT Inc.
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences. Shares of AUXL fell by 0.57% or $-0.17/share to $29.76. In the past year, the shares have traded as low as $16.36 and as high as $32.89. On average, 1463120 shares of AUXL exchange hands on a given day and today's volume is recorded at 1639239.
QLT Inc., is a biotechnology company. The Company is engaged in the development and commercialization of ocular products. Shares of QLT fell by 1.09% or $-0.05/share to $4.53. In the past year, the shares have traded as low as $4.45 and as high as $7.90. On average, 3600 shares of QLT.TO exchange hands on a given day and today's volume is recorded at 550.
QLT Inc., is a biotechnology company. The Company is engaged in the development and commercialization of ocular products. Shares of QLTI fell by 1.22% or $-0.05/share to $4.04. In the past year, the shares have traded as low as $4.00 and as high as $7.10. On average, 138309 shares of QLTI exchange hands on a given day and today's volume is recorded at 43500.
Source
